首页 > 最新文献

DARU Journal of Pharmaceutical Sciences最新文献

英文 中文
Recent opportunities and application of gellan gum based drug delivery system for intranasal route. 基于结冷胶的鼻内给药系统的最新机遇和应用。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-01 Epub Date: 2024-10-03 DOI: 10.1007/s40199-024-00543-w
Anuj Garg, Khushboo Lavania

Objectives: In the recent years, in-situ hydrogel based on gellan gum has been investigated for delivery of various drug molecules particularly to treat neurological disorders via intranasal route. The major objective of the present manuscript is to review the recent research studies exploring gellan gum as ionic triggered in-situ gel for intranasal administration to enhance absorption of drugs and to increase their therapeutic efficacy.

Methods: This review include literature from 1982 to 2023 and were collected from various scientific electronic databases like Scopus, PubMed and Google Scholar to review source, chemistry, ionotropic gelation mechanism, and recent research studies for gellan gum based in-situ hydrogel for intransasl administration.Keywords such as gellan gum, in-situ hydrogel, intranasal administration and brain targeting were used to search literature. The present review included the research studies which explored gellan gum based in-situ gel for intranasal drug delivery.

Results: The findings have shown enhanced biavailability of various drugs upon intranasal administration using gellan-gum based in-situ hydrogel.Moreover, the review indicated that intranasal administration of in-situ hydrogel facilitate to overcome blood brain barrier effectively. Hence, significantly higher drug concentration was found to be achieved in brain tissues upon intranasal administration than that of other routes like oral and intravenous.

Conclusion: The present work conducted a comprehensive review for gellan gum based in-situ hydrogel particularly for intransal administration to overcome BBB. The study concluded that gellan gum based in-situ hydrogel could be potential promising delivery system for intranasal administration to improve bioavailability and efficacy of drugs specifically to treat neurological disorders.

研究目的近年来,人们一直在研究基于结冷胶的原位水凝胶,用于输送各种药物分子,特别是通过鼻内途径治疗神经系统疾病。本手稿的主要目的是综述最近的研究,探讨将结冷胶作为离子触发原位凝胶用于鼻内给药,以促进药物吸收并提高疗效:本综述包括1982年至2023年的文献,从Scopus、PubMed和Google Scholar等各种科学电子数据库中收集,以综述基于结冷胶的原位水凝胶用于鼻内给药的来源、化学、离子触发凝胶机制和最新研究。本综述包括探讨基于结冷胶的原位凝胶用于鼻内给药的研究:结果:研究结果表明,使用结冷胶原位水凝胶鼻内给药可提高各种药物的生物利用度。因此,与口服和静脉注射等其他途径相比,鼻内给药在脑组织中达到的药物浓度明显更高:本研究对基于结冷胶的原位水凝胶,尤其是用于经口给药以克服血脑屏障的原位水凝胶进行了全面综述。研究认为,基于结冷胶的原位水凝胶可能是一种有潜力的鼻内给药系统,可提高药物的生物利用度和疗效,特别是在治疗神经系统疾病方面。
{"title":"Recent opportunities and application of gellan gum based drug delivery system for intranasal route.","authors":"Anuj Garg, Khushboo Lavania","doi":"10.1007/s40199-024-00543-w","DOIUrl":"10.1007/s40199-024-00543-w","url":null,"abstract":"<p><strong>Objectives: </strong>In the recent years, in-situ hydrogel based on gellan gum has been investigated for delivery of various drug molecules particularly to treat neurological disorders via intranasal route. The major objective of the present manuscript is to review the recent research studies exploring gellan gum as ionic triggered in-situ gel for intranasal administration to enhance absorption of drugs and to increase their therapeutic efficacy.</p><p><strong>Methods: </strong>This review include literature from 1982 to 2023 and were collected from various scientific electronic databases like Scopus, PubMed and Google Scholar to review source, chemistry, ionotropic gelation mechanism, and recent research studies for gellan gum based in-situ hydrogel for intransasl administration.Keywords such as gellan gum, in-situ hydrogel, intranasal administration and brain targeting were used to search literature. The present review included the research studies which explored gellan gum based in-situ gel for intranasal drug delivery.</p><p><strong>Results: </strong>The findings have shown enhanced biavailability of various drugs upon intranasal administration using gellan-gum based in-situ hydrogel.Moreover, the review indicated that intranasal administration of in-situ hydrogel facilitate to overcome blood brain barrier effectively. Hence, significantly higher drug concentration was found to be achieved in brain tissues upon intranasal administration than that of other routes like oral and intravenous.</p><p><strong>Conclusion: </strong>The present work conducted a comprehensive review for gellan gum based in-situ hydrogel particularly for intransal administration to overcome BBB. The study concluded that gellan gum based in-situ hydrogel could be potential promising delivery system for intranasal administration to improve bioavailability and efficacy of drugs specifically to treat neurological disorders.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"947-965"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of the treatment of iron deficiency anemia on chronic drug-resistant cough: a rare case report. 缺铁性贫血治疗对慢性耐药性咳嗽的影响:罕见病例报告。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-01 Epub Date: 2024-06-08 DOI: 10.1007/s40199-024-00522-1
Fatemeh Akbari, Lale Vahedi Larijani, Ehsan Rajabi Visroodi, Bahareh Hakiminia

Background: A persistent difficult-to-treat cough can be exhausting. Iron is an essential element that plays an important role in regulating the production of pro-inflammatory cytokines, and its deficiency may potentiate airway inflammation and dysfunction. There is a paucity of data regarding a link between iron deficiency (ID) and idiopathic cough.

Objectives: In this study, a case of persistent non-productive cough, which was unresponsive to targeted treatment approaches but responsive to iron therapy, is reported.

Methods: A 53-year-old woman came to a medical clinic with complaints of a chronic and progressive non-productive cough. She underwent a complete clinical and paraclinical evaluation.

Results: Her vital signs were stable and no abnormalities were found on the physical examination. The results of the spirometry and chest radiography were unremarkable. The laboratory test indicated hypochromic microcytic anemia, with a hemoglobin value of 9.6 g/dL. Her cough was resolved after treatment of iron-deficiency anemia with an oral nutraceutical capsule containing 28 mg of elemental iron (as ferrous bis-glycinate) plus folic acid, vitamin B12, and vitamin C, once daily for six months.

Conclusion: In the case of unexplained chronic cough, resistant to targeted therapies, investigation and treatment of ID may contribute to the resolution of cough.

背景介绍久治不愈的咳嗽会让人疲惫不堪。铁是一种必需元素,在调节促炎细胞因子的产生方面发挥着重要作用,缺铁可能会加剧气道炎症和功能障碍。有关缺铁(ID)与特发性咳嗽之间联系的数据还很少:本研究报告了一例持续性无痰咳嗽病例,该病例对靶向治疗方法无反应,但对铁治疗有反应:一名 53 岁的女性因慢性进行性无痰咳嗽来到一家医疗诊所就诊。她接受了全面的临床和辅助临床评估:结果:她的生命体征平稳,体格检查未发现异常。肺活量和胸片检查结果均无异常。实验室检查显示为低色素性小细胞性贫血,血红蛋白值为 9.6 g/dL。在口服含 28 毫克元素铁(以甘氨酸亚铁的形式)外加叶酸、维生素 B12 和维生素 C 的营养保健胶囊治疗缺铁性贫血后,她的咳嗽缓解了,每天一次,连续服用了 6 个月:结论:对于对靶向疗法耐药的不明原因的慢性咳嗽,调查和治疗 ID 可能有助于咳嗽的缓解。
{"title":"Effect of the treatment of iron deficiency anemia on chronic drug-resistant cough: a rare case report.","authors":"Fatemeh Akbari, Lale Vahedi Larijani, Ehsan Rajabi Visroodi, Bahareh Hakiminia","doi":"10.1007/s40199-024-00522-1","DOIUrl":"10.1007/s40199-024-00522-1","url":null,"abstract":"<p><strong>Background: </strong>A persistent difficult-to-treat cough can be exhausting. Iron is an essential element that plays an important role in regulating the production of pro-inflammatory cytokines, and its deficiency may potentiate airway inflammation and dysfunction. There is a paucity of data regarding a link between iron deficiency (ID) and idiopathic cough.</p><p><strong>Objectives: </strong>In this study, a case of persistent non-productive cough, which was unresponsive to targeted treatment approaches but responsive to iron therapy, is reported.</p><p><strong>Methods: </strong>A 53-year-old woman came to a medical clinic with complaints of a chronic and progressive non-productive cough. She underwent a complete clinical and paraclinical evaluation.</p><p><strong>Results: </strong>Her vital signs were stable and no abnormalities were found on the physical examination. The results of the spirometry and chest radiography were unremarkable. The laboratory test indicated hypochromic microcytic anemia, with a hemoglobin value of 9.6 g/dL. Her cough was resolved after treatment of iron-deficiency anemia with an oral nutraceutical capsule containing 28 mg of elemental iron (as ferrous bis-glycinate) plus folic acid, vitamin B12, and vitamin C, once daily for six months.</p><p><strong>Conclusion: </strong>In the case of unexplained chronic cough, resistant to targeted therapies, investigation and treatment of ID may contribute to the resolution of cough.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"967-971"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A synthetic curcumin-like diarylpentanoid analog inhibits rhinovirus infection in H1 hela cells via multiple antiviral mechanisms. 一种合成姜黄素类二元戊烷类似物通过多种抗病毒机制抑制 H1 hela 细胞中的鼻病毒感染。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-01 Epub Date: 2024-10-12 DOI: 10.1007/s40199-024-00542-x
Kong Yen Liew, Hui-Yee Chee, Faridah Abas, Sze Wei Leong, Hanis Hazeera Harith, Daud Ahmad Israf, Mohd Roslan Sulaiman, Chau Ling Tham

Background: Rhinovirus (RV) infection is a major cause of common colds and asthma exacerbations, with no antiviral drug available. Curcumin exhibits broad-spectrum antiviral activities, but its therapeutic effect is limited by a poor pharmacokinetics profile. Curcumin-like diarylpentanoid analogs, particularly 2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohexen-1-ol (BDHBC) and 5-(3,4-dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl)penta-2,4-dien-1-one (DHHPD), have better solubility and stability compared to curcumin.

Objectives: Therefore, this study aims to evaluate and compare the antiviral effects of curcumin, BDHBC, and DHHPD in an in vitro model of RV infection.

Methods: The inhibitory effects on RV-16 infection in H1 HeLa cells were assessed using cytopathic effect (CPE) reduction assay, virus yield reduction assay, RT-qPCR, and Western blot. Antiviral effects in different modes of treatment (pre-, co-, and post-treatment) were also compared. Additionally, intercellular adhesion molecule 1 (ICAM-1) expression, RV binding, and infectivity were measured with Western blot, flow cytometry, and virucidal assay, respectively.

Results: When used as a post-treatment, BDHBC (EC50: 4.19 µM; SI: 8.32) demonstrated stronger antiviral potential on RV-16 compared to DHHPD (EC50: 18.24 µM; SI: 1.82) and curcumin (less than 50% inhibition). BDHBC also showed the strongest inhibitory effect on RV-induced CPE, virus yield, vRNA, and viral proteins (P1, VP0, and VP2). Furthermore, BDHBC pre-treatment has a prophylactic effect against RV infection, which was attributed to reduced basal expression of ICAM-1. However, it did not affect virus binding, but exerted virucidal activity on RV-16, contributing to its antiviral effect during co-treatment.

Conclusion: BDHBC exhibits multiple antiviral mechanisms against RV infection and thus could be a potential antiviral agent for RV.

背景:鼻病毒(RV)感染是普通感冒和哮喘恶化的主要原因,目前尚无抗病毒药物。姜黄素具有广谱抗病毒活性,但其治疗效果因药代动力学特征不佳而受到限制。姜黄素类二元戊环类似物,尤其是 2-苯甲酰基-6-(3,4-二羟基亚苄基)环己烯-1-醇(BDHBC)和 5-(3,4-二羟基苯基)-3-羟基-1-(2-羟基苯基)戊-2,4-二烯-1-酮(DHHPD),与姜黄素相比具有更好的溶解性和稳定性:因此,本研究旨在评估和比较姜黄素、BDHBC和DHHPD在体外RV感染模型中的抗病毒作用:方法: 采用细胞病理效应(CPE)降低试验、病毒产量降低试验、RT-qPCR 和 Western 印迹法评估姜黄素、BDHBC 和 DHHPD 对 H1 HeLa 细胞中 RV-16 感染的抑制作用。还比较了不同治疗模式(治疗前、治疗中和治疗后)的抗病毒效果。此外,还分别用 Western 印迹、流式细胞仪和杀病毒剂测定了细胞间粘附分子 1(ICAM-1)的表达、RV 结合力和感染力:与DHHPD(EC50:18.24 µM;SI:1.82)和姜黄素(抑制率低于50%)相比,BDHBC(EC50:4.19 µM;SI:8.32)作为后处理对RV-16表现出更强的抗病毒潜力。BDHBC 对 RV 诱导的 CPE、病毒产量、vRNA 和病毒蛋白(P1、VP0 和 VP2)也表现出最强的抑制作用。此外,BDHBC 预处理对 RV 感染有预防作用,这归因于 ICAM-1 的基础表达减少。然而,BDHBC并不影响病毒的结合,但对RV-16具有杀病毒活性,这也是其在联合处理期间具有抗病毒作用的原因:结论:BDHBC 对 RV 感染具有多种抗病毒机制,因此可能是一种潜在的 RV 抗病毒药物。
{"title":"A synthetic curcumin-like diarylpentanoid analog inhibits rhinovirus infection in H1 hela cells via multiple antiviral mechanisms.","authors":"Kong Yen Liew, Hui-Yee Chee, Faridah Abas, Sze Wei Leong, Hanis Hazeera Harith, Daud Ahmad Israf, Mohd Roslan Sulaiman, Chau Ling Tham","doi":"10.1007/s40199-024-00542-x","DOIUrl":"10.1007/s40199-024-00542-x","url":null,"abstract":"<p><strong>Background: </strong>Rhinovirus (RV) infection is a major cause of common colds and asthma exacerbations, with no antiviral drug available. Curcumin exhibits broad-spectrum antiviral activities, but its therapeutic effect is limited by a poor pharmacokinetics profile. Curcumin-like diarylpentanoid analogs, particularly 2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohexen-1-ol (BDHBC) and 5-(3,4-dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl)penta-2,4-dien-1-one (DHHPD), have better solubility and stability compared to curcumin.</p><p><strong>Objectives: </strong>Therefore, this study aims to evaluate and compare the antiviral effects of curcumin, BDHBC, and DHHPD in an in vitro model of RV infection.</p><p><strong>Methods: </strong>The inhibitory effects on RV-16 infection in H1 HeLa cells were assessed using cytopathic effect (CPE) reduction assay, virus yield reduction assay, RT-qPCR, and Western blot. Antiviral effects in different modes of treatment (pre-, co-, and post-treatment) were also compared. Additionally, intercellular adhesion molecule 1 (ICAM-1) expression, RV binding, and infectivity were measured with Western blot, flow cytometry, and virucidal assay, respectively.</p><p><strong>Results: </strong>When used as a post-treatment, BDHBC (EC<sub>50</sub>: 4.19 µM; SI: 8.32) demonstrated stronger antiviral potential on RV-16 compared to DHHPD (EC<sub>50</sub>: 18.24 µM; SI: 1.82) and curcumin (less than 50% inhibition). BDHBC also showed the strongest inhibitory effect on RV-induced CPE, virus yield, vRNA, and viral proteins (P1, VP0, and VP2). Furthermore, BDHBC pre-treatment has a prophylactic effect against RV infection, which was attributed to reduced basal expression of ICAM-1. However, it did not affect virus binding, but exerted virucidal activity on RV-16, contributing to its antiviral effect during co-treatment.</p><p><strong>Conclusion: </strong>BDHBC exhibits multiple antiviral mechanisms against RV infection and thus could be a potential antiviral agent for RV.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"729-744"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relieving postherpetic neuralgia pain via gabapentin-loaded bigels as an auspicious topical drug delivery system. 通过加载加巴喷丁的 BIGELS 作为吉祥的局部给药系统缓解带状疱疹后神经痛的疼痛。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-01 Epub Date: 2024-10-08 DOI: 10.1007/s40199-024-00541-y
Wessam H Abd-Elsalam, Abdulaziz Mohsen Al-Mahallawi, Amal Makhlouf

Background: Over the past decades, a substantial portion of the population worldwide has been infected with varicella zoster and most cases developed shingles. Unfortunately, shingles is usually accompanied by postherpetic neuralgia, which may persist for months to years after the resolution of the viral infection.

Objectives: Gabapentin is an orally gamma-aminobutyric acid analogue approved by the Food and Drug Administration to manage shingles postherpetic neuralgia. However, gabapentin shows nonlinear pharmacokinetics, with variable absorption and bioavailability along with its short half-life and long side effects that may include dizziness and somnolence, which calls for an appropriate topical dosage form. Bigels are unique semisolid dosage forms with boosted penetrability and satisfactory hydrophilic texture.

Methods: The current work pointed to formulating gabapentin-loaded bigels for the treatment of postherpetic neuralgia, where the analysis and optimization of design were performed via Design-Expert®.

Results and conclusions: The selected bigel (F5), incorporating 400 mg Span 60, 1000 mg Tween 80, and 1000 mg Transcutol, displayed spherical nanosized particles with acceptable viscosity and spreadability. Subsequent topical application of the selected bigel on the skin of Wistar rats, F5, demonstrated a boosted accumulation of gabapentin in the skin similar to PLO gel but superior to the drug solution. Furthermore, a histopathological study demonstrated the biosafety of the selected bigel when applied topically. Accordingly, gabapentin-loaded bigel would be considered a potentially topical dosage form for the delivery of gabapentin for the management of postherpetic neuralgia.

背景:在过去的几十年里,全球有相当一部分人感染了水痘带状疱疹,大多数病例都患上了带状疱疹。不幸的是,带状疱疹通常伴有带状疱疹后遗神经痛,这种疼痛可能在病毒感染缓解后持续数月至数年:加巴喷丁是一种口服γ-氨基丁酸类似物,已被美国食品和药物管理局批准用于治疗带状疱疹后遗神经痛。然而,加巴喷丁显示出非线性药代动力学,其吸收和生物利用度不稳定,半衰期短,副作用长,可能包括头晕和嗜睡,因此需要一种合适的外用剂型。Bigels 是一种独特的半固体剂型,具有增强的渗透性和令人满意的亲水性质地:方法:目前的工作旨在配制加巴喷丁的 bigels 用于治疗带状疱疹后神经痛,并通过 Design-Expert® 进行了分析和优化设计:选定的 bigel(F5)含有 400 毫克 Span 60、1000 毫克 Tween 80 和 1000 毫克 Transcutol,呈球形纳米颗粒,具有可接受的粘度和涂抹性。随后在 Wistar 大鼠皮肤上局部涂抹选定的 bigel(F5),结果表明加巴喷丁在皮肤中的蓄积量增加,与 PLO 凝胶相似,但优于药物溶液。此外,一项组织病理学研究表明,选定的 bigel 局部使用时具有生物安全性。因此,加载了加巴喷丁的 bigel 被认为是一种可用于治疗带状疱疹后神经痛的加巴喷丁外用剂型。
{"title":"Relieving postherpetic neuralgia pain via gabapentin-loaded bigels as an auspicious topical drug delivery system.","authors":"Wessam H Abd-Elsalam, Abdulaziz Mohsen Al-Mahallawi, Amal Makhlouf","doi":"10.1007/s40199-024-00541-y","DOIUrl":"10.1007/s40199-024-00541-y","url":null,"abstract":"<p><strong>Background: </strong>Over the past decades, a substantial portion of the population worldwide has been infected with varicella zoster and most cases developed shingles. Unfortunately, shingles is usually accompanied by postherpetic neuralgia, which may persist for months to years after the resolution of the viral infection.</p><p><strong>Objectives: </strong>Gabapentin is an orally gamma-aminobutyric acid analogue approved by the Food and Drug Administration to manage shingles postherpetic neuralgia. However, gabapentin shows nonlinear pharmacokinetics, with variable absorption and bioavailability along with its short half-life and long side effects that may include dizziness and somnolence, which calls for an appropriate topical dosage form. Bigels are unique semisolid dosage forms with boosted penetrability and satisfactory hydrophilic texture.</p><p><strong>Methods: </strong>The current work pointed to formulating gabapentin-loaded bigels for the treatment of postherpetic neuralgia, where the analysis and optimization of design were performed via Design-Expert®.</p><p><strong>Results and conclusions: </strong>The selected bigel (F5), incorporating 400 mg Span 60, 1000 mg Tween 80, and 1000 mg Transcutol, displayed spherical nanosized particles with acceptable viscosity and spreadability. Subsequent topical application of the selected bigel on the skin of Wistar rats, F5, demonstrated a boosted accumulation of gabapentin in the skin similar to PLO gel but superior to the drug solution. Furthermore, a histopathological study demonstrated the biosafety of the selected bigel when applied topically. Accordingly, gabapentin-loaded bigel would be considered a potentially topical dosage form for the delivery of gabapentin for the management of postherpetic neuralgia.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"705-714"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dispersive micro-solid phase extraction based on two MOFs as highly effective adsorbents for analysis of nilotinib in plasma and wastewater. 基于两种 MOFs 高效吸附剂的分散微固相萃取用于血浆和废水中尼洛替尼的分析。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-01 Epub Date: 2024-08-13 DOI: 10.1007/s40199-024-00531-0
Azra Takhvar, Somaye Akbari, Effat Souri, Reza Ahmadkhaniha, Ali Morsali, Mohammad Reza Khoshayand, Mohsen Amini, Alireza Taheri

Background: Nilotinib (NIL) is a prescription medication employed in the treatment of specific types of leukemia, namely chronic myelogenous leukemia (CML). The determination of NIL levels in patients undergoing treatment for CML is of paramount importance for effective management of treatment and toxicity. Also, monitoring and controlling its level in wastewater sources could help scientists to identify potential hotspots of contamination and take appropriate measures to mitigate their impact on the environment and public health.

Objectives: This study presents a D-µ-SPE technique utilizing two MOFs as adsorbents for the efficient detection of nilotinib in plasma and wastewater samples for the first time.

Methods: Two highly effective MOFs, MIL-101(Fe) and MIL-53(Al), were synthesized and applied as dispersive micro-solid phase extraction (D-µ-SPE) adsorbents for the extraction of nilotinib coupled with HPLC-UV in a short time of analysis. Experimental parameters affecting extraction efficacy such as adsorbent amount, ionic strength, pH value, adsorption-desorption time and type of elution solvent, were optimized.

Results: Under optimal experimental conditions, the linear dynamic was achieved in the range of 0.25-5.00 µg/mL in human plasma and 0.01-0.20 µg/mL in wastewater. The extraction recovery was in the range of 89.18-91.53% and 94.39-99.60% for nilotinib and MIL-101(Fe) and also 91.22-97.35% and 98.14-100.78% for nilotinib and MIL-53(Al) from human plasma and wastewater respectively.

Conclusion: HPLC-UV determination of nilotinib after the D-µ-SPE method showed acceptable accuracy and precision in both plasma and wastewater. In comparison between the two adsorbents, the extraction procedure was easier and faster with MIL-53(Al) as the adsorbent.

背景:尼罗替尼(NIL)是一种处方药,用于治疗特定类型的白血病,即慢性粒细胞白血病(CML)。测定接受 CML 治疗的患者体内的 NIL 含量对于有效控制治疗和毒性至关重要。此外,监测和控制废水源中的 NIL 水平有助于科学家确定潜在的污染热点,并采取适当措施减轻其对环境和公众健康的影响:本研究首次提出了一种利用两种MOFs作为吸附剂的D-µ-SPE技术,用于高效检测血浆和废水样品中的尼洛替尼:合成并应用两种高效MOFs--MIL-101(Fe)和MIL-53(Al)作为分散微固相萃取(D-µ-SPE)吸附剂,结合高效液相色谱-紫外光谱法在短时间内萃取尼洛替尼。对吸附剂用量、离子强度、pH 值、吸附-解吸时间和洗脱溶剂类型等影响萃取效果的实验参数进行了优化:在最佳实验条件下,人血浆中的线性动态范围为 0.25-5.00 µg/mL ,废水中的线性动态范围为 0.01-0.20 µg/mL。尼洛替尼和MIL-101(Fe)的提取回收率分别为89.18%-91.53%和94.39%-99.60%,尼洛替尼和MIL-53(Al)在人体血浆和废水中的提取回收率分别为91.22%-97.35%和98.14%-100.78%:采用 D-µ-SPE 法测定血浆和废水中的尼洛替尼时,HPLC-UV 显示出了可接受的准确度和精密度。两种吸附剂相比,以 MIL-53(Al)为吸附剂的提取过程更简单、更快速。
{"title":"Dispersive micro-solid phase extraction based on two MOFs as highly effective adsorbents for analysis of nilotinib in plasma and wastewater.","authors":"Azra Takhvar, Somaye Akbari, Effat Souri, Reza Ahmadkhaniha, Ali Morsali, Mohammad Reza Khoshayand, Mohsen Amini, Alireza Taheri","doi":"10.1007/s40199-024-00531-0","DOIUrl":"10.1007/s40199-024-00531-0","url":null,"abstract":"<p><strong>Background: </strong>Nilotinib (NIL) is a prescription medication employed in the treatment of specific types of leukemia, namely chronic myelogenous leukemia (CML). The determination of NIL levels in patients undergoing treatment for CML is of paramount importance for effective management of treatment and toxicity. Also, monitoring and controlling its level in wastewater sources could help scientists to identify potential hotspots of contamination and take appropriate measures to mitigate their impact on the environment and public health.</p><p><strong>Objectives: </strong>This study presents a D-µ-SPE technique utilizing two MOFs as adsorbents for the efficient detection of nilotinib in plasma and wastewater samples for the first time.</p><p><strong>Methods: </strong>Two highly effective MOFs, MIL-101(Fe) and MIL-53(Al), were synthesized and applied as dispersive micro-solid phase extraction (D-µ-SPE) adsorbents for the extraction of nilotinib coupled with HPLC-UV in a short time of analysis. Experimental parameters affecting extraction efficacy such as adsorbent amount, ionic strength, pH value, adsorption-desorption time and type of elution solvent, were optimized.</p><p><strong>Results: </strong>Under optimal experimental conditions, the linear dynamic was achieved in the range of 0.25-5.00 µg/mL in human plasma and 0.01-0.20 µg/mL in wastewater. The extraction recovery was in the range of 89.18-91.53% and 94.39-99.60% for nilotinib and MIL-101(Fe) and also 91.22-97.35% and 98.14-100.78% for nilotinib and MIL-53(Al) from human plasma and wastewater respectively.</p><p><strong>Conclusion: </strong>HPLC-UV determination of nilotinib after the D-µ-SPE method showed acceptable accuracy and precision in both plasma and wastewater. In comparison between the two adsorbents, the extraction procedure was easier and faster with MIL-53(Al) as the adsorbent.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"617-630"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A review of the ethnomedicinal, phytochemical, and pharmacological properties of the Ferulago genus based on Structure-Activity Relationship (SAR) of coumarins. 基于香豆素的结构-活性关系(SAR),综述阿魏属植物的民族药用、植物化学和药理特性。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-01 Epub Date: 2024-08-19 DOI: 10.1007/s40199-024-00530-1
Farid Dabaghian, Shokoufeh Aalinezhad, Alaleh Riazati Kesheh, Niloufar Azargashb, Ramin Ansari, Mohammad Reza Shams Ardekani, Seyed Ahmad Emami, Mahnaz Khanavi, Mohammad Reza Delnavazi

Background: The Ferluago W.D.J. Koch genus includes 48 accepted perennial herbs that are distributed in the Mediterranean region, Southeast Europe, Central and Middle East of Asia. These plants are widely used in folk and conventional medicine due to their biological benefits such as anti-microbial, anti-inflammatory, anti-cancer, and immunomodulatory properties. Conducting a comprehensive review based on the structure activity relationships (SARs) of the coumarins, which has not been previously documented, can lead to a better insight into the genus Ferulago and its beneficial therapeutic activities.

Methods: This review covers literature from 1969 to 2023, were collected from various scientific electronic databases to review phytochemical, pharmacological, and ethnopharmacological data of Ferulago species, as well as latest information on the SAR of reported coumarins from this genus.

Results: Phytochemical studies showed that the biological actions of this genus are mediated by the reported specialized metabolites, such as coumarins and flavonoids. Simple coumarins, prenylated coumarins, furanocoumarins, and pyranocoumarins are the largest subclasses of coumarins found in diverse Ferulago species, which have discussed the biological effects of them with a focus on the Structure-Activity Relationship (SAR). For example, prenylated coumarins have shown potential leishmanicidal and anti-neuropsychiatric effects when substituted with a prenyl group at the 7-hydroxy, as well as the C6 and C8 positions in their scaffold. Similarly, furanocoumarins exhibit varied biological activities such as anti-inflammatory, anti-proliferative, and anti-convulsant effects. Modifying substitutions at the C5 and C6 positions in furanocoumarins can enhance these activities.

Conclusion: This study conducted a comprehensive review of all available information on the phytochemical and pharmacological characteristics of Ferulago species. Given the high occurrence of coumarins in this genus, which exhibit potential anti-Alzheimer and anti-microbial properties, it presents promising new therapeutic avenues for addressing these common issues. Further investigation is needed to understand the molecular-level mechanisms of action and to explore their clinical applications.

背景:Ferluago W.D.J. Koch 属包括 48 种公认的多年生草本植物,分布于地中海地区、欧洲东南部、亚洲中部和中东。这些植物具有抗微生物、抗炎、抗癌和免疫调节等生物功效,因此被广泛应用于民间和传统医学中。根据香豆素的结构活性关系(SARs)进行全面综述,可以更好地了解阿魏属植物及其有益的治疗活动:本综述从各种科学电子数据库中收集了1969年至2023年的文献,综述了Ferulago属植物的植物化学、药理学和民族药理学数据,以及该属已报道的香豆素SAR的最新信息:植物化学研究表明,该属植物的生物作用是由所报道的特殊代谢产物(如香豆素和黄酮类化合物)介导的。简单香豆素、前酰化香豆素、呋喃香豆素和吡喃香豆素是在不同的阿魏属植物中发现的最大的香豆素亚类,这些香豆素亚类以结构-活性关系(SAR)为重点讨论了它们的生物效应。例如,当7-羟基以及C6和C8位置上的芳基被取代时,芳基香豆素就显示出了潜在的杀利什曼和抗神经精神作用。同样,呋喃香豆素也具有多种生物活性,如抗炎、抗增殖和抗惊厥作用。在呋喃香豆素的 C5 和 C6 位置进行修饰取代可增强这些活性:本研究对有关阿魏属植物的植物化学和药理特性的所有可用信息进行了全面回顾。鉴于该属植物中含有大量香豆素,具有潜在的抗老年痴呆和抗微生物特性,这为解决这些常见问题提供了新的治疗途径。要了解其分子水平的作用机制并探索其临床应用,还需要进一步的研究。
{"title":"A review of the ethnomedicinal, phytochemical, and pharmacological properties of the Ferulago genus based on Structure-Activity Relationship (SAR) of coumarins.","authors":"Farid Dabaghian, Shokoufeh Aalinezhad, Alaleh Riazati Kesheh, Niloufar Azargashb, Ramin Ansari, Mohammad Reza Shams Ardekani, Seyed Ahmad Emami, Mahnaz Khanavi, Mohammad Reza Delnavazi","doi":"10.1007/s40199-024-00530-1","DOIUrl":"10.1007/s40199-024-00530-1","url":null,"abstract":"<p><strong>Background: </strong>The Ferluago W.D.J. Koch genus includes 48 accepted perennial herbs that are distributed in the Mediterranean region, Southeast Europe, Central and Middle East of Asia. These plants are widely used in folk and conventional medicine due to their biological benefits such as anti-microbial, anti-inflammatory, anti-cancer, and immunomodulatory properties. Conducting a comprehensive review based on the structure activity relationships (SARs) of the coumarins, which has not been previously documented, can lead to a better insight into the genus Ferulago and its beneficial therapeutic activities.</p><p><strong>Methods: </strong>This review covers literature from 1969 to 2023, were collected from various scientific electronic databases to review phytochemical, pharmacological, and ethnopharmacological data of Ferulago species, as well as latest information on the SAR of reported coumarins from this genus.</p><p><strong>Results: </strong>Phytochemical studies showed that the biological actions of this genus are mediated by the reported specialized metabolites, such as coumarins and flavonoids. Simple coumarins, prenylated coumarins, furanocoumarins, and pyranocoumarins are the largest subclasses of coumarins found in diverse Ferulago species, which have discussed the biological effects of them with a focus on the Structure-Activity Relationship (SAR). For example, prenylated coumarins have shown potential leishmanicidal and anti-neuropsychiatric effects when substituted with a prenyl group at the 7-hydroxy, as well as the C<sub>6</sub> and C<sub>8</sub> positions in their scaffold. Similarly, furanocoumarins exhibit varied biological activities such as anti-inflammatory, anti-proliferative, and anti-convulsant effects. Modifying substitutions at the C<sub>5</sub> and C<sub>6</sub> positions in furanocoumarins can enhance these activities.</p><p><strong>Conclusion: </strong>This study conducted a comprehensive review of all available information on the phytochemical and pharmacological characteristics of Ferulago species. Given the high occurrence of coumarins in this genus, which exhibit potential anti-Alzheimer and anti-microbial properties, it presents promising new therapeutic avenues for addressing these common issues. Further investigation is needed to understand the molecular-level mechanisms of action and to explore their clinical applications.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"825-899"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Active pharmaceutical contaminants in drinking water: myth or fact? 饮用水中的活性药物污染物:传说还是事实?
IF 3.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-18 DOI: 10.1007/s40199-024-00536-9
Zvanaka Mazhandu, Tebogo Mashifana
<p>Global water availability has been affected by a variety of factors, including climate change, water pollution, urbanization, and population growth. These issues have been particularly acute in many parts of the world, where access to clean water remains a significant challenge. In this context, preserving existing water bodies is a critical priority. Numerous studies have demonstrated the inadequacy of conventional water treatment processes in removing active pharmaceutical ingredients (APIs) from the water. These pharmaceutical active compounds have been detected in treated wastewater, groundwater, and even drinking water sources. The presence of APIs in water resources poses a significant threat not only to aquatic organisms but also to human health. These emerging contaminants have the potential to disrupt endocrine systems, promote the development of antibiotic-resistant bacteria, and bioaccumulate in the food chain, ultimately leading to unacceptable risks to public health. The inability of current conventional treatment methods to effectively remove APIs from water has raised serious concerns about the safety and reliability of water supplies. This issue requires immediate attention and the development of more effective treatment technologies to safeguard the quality of water resources and protect both aquatic ecosystems and human health. Other treatment methods, such as nanotechnology, microalgal treatment, and reverse osmosis, are promising in addressing the issue of API contamination in water resources. These innovative approaches have demonstrated higher removal efficiencies for a wide range of APIs compared to conventional methods, such as activated sludge and chlorination, which have been found to be inadequate in the removal of these emerging contaminants. The potential of these alternative treatment technologies to serve as effective tertiary treatment. To address this critical challenge, governments and policymakers should prioritize investment in research and development to establish effective and scalable solutions for eliminating APIs from various water sources. This should include comprehensive studies to assess the performance, cost-effectiveness, and environmental sustainability of emerging treatment technologies. The emerging contaminants should be included in robust water quality monitoring programs (Aus der Beek et al. in Environ Toxicol Chem 2016;35(4):823-835), with strict regulatory limits enforced to protect public health and the environment. By doing so, the scientific community and regulatory authorities can work together to develop a multi-barrier approach to safeguarding the water resources and ensuring access to safe, clean water for all. This review explores the potential of alternative treatment technologies to serve as viable solutions in the fight against API contamination. Innovative approaches, including nanotechnology, microalgal treatment, and reverse osmosis, have demonstrated remarkable success in ad
全球水供应受到气候变化、水污染、城市化和人口增长等多种因素的影响。这些问题在世界许多地区尤为突出,在这些地区,获取清洁水源仍然是一项重大挑战。在这种情况下,保护现有水体是一个至关重要的优先事项。大量研究表明,传统的水处理工艺不足以去除水中的活性药物成分 (API)。在经过处理的废水、地下水甚至饮用水源中都检测到了这些药物活性化合物。水资源中存在的 API 不仅对水生生物,而且对人类健康都构成了重大威胁。这些新出现的污染物有可能扰乱内分泌系统,促进抗生素耐药细菌的发展,并在食物链中进行生物累积,最终给公众健康带来不可接受的风险。目前的传统处理方法无法有效去除水中的原料药,这引起了人们对供水安全性和可靠性的严重担忧。需要立即关注这一问题,并开发更有效的处理技术,以保障水资源的质量,保护水生生态系统和人类健康。其他处理方法,如纳米技术、微藻处理和反渗透技术,在解决水资源中的原料药污染问题方面大有可为。与传统方法(如活性污泥法和氯化法)相比,这些创新方法对多种 API 的去除率更高。这些替代处理技术具有作为有效三级处理的潜力。为应对这一严峻挑战,各国政府和政策制定者应优先投资于研发,以建立有效且可扩展的解决方案,消除各种水源中的原料药。这应包括对新兴处理技术的性能、成本效益和环境可持续性进行评估的综合研究。新兴污染物应纳入强有力的水质监测计划(Aus der Beek 等人,载于 Environ Toxicol Chem 2016;35(4):823-835),并实施严格的监管限制,以保护公众健康和环境。通过这样做,科学界和监管当局可以共同制定一种多屏障方法来保护水资源,并确保所有人都能获得安全、清洁的水。本综述探讨了替代处理技术作为抗击原料药污染的可行解决方案的潜力。包括纳米技术、微藻处理和反渗透在内的创新方法在应对这一挑战方面取得了显著的成功,与传统方法相比,它们具有更高的去除效率。
{"title":"Active pharmaceutical contaminants in drinking water: myth or fact?","authors":"Zvanaka Mazhandu, Tebogo Mashifana","doi":"10.1007/s40199-024-00536-9","DOIUrl":"https://doi.org/10.1007/s40199-024-00536-9","url":null,"abstract":"&lt;p&gt;Global water availability has been affected by a variety of factors, including climate change, water pollution, urbanization, and population growth. These issues have been particularly acute in many parts of the world, where access to clean water remains a significant challenge. In this context, preserving existing water bodies is a critical priority. Numerous studies have demonstrated the inadequacy of conventional water treatment processes in removing active pharmaceutical ingredients (APIs) from the water. These pharmaceutical active compounds have been detected in treated wastewater, groundwater, and even drinking water sources. The presence of APIs in water resources poses a significant threat not only to aquatic organisms but also to human health. These emerging contaminants have the potential to disrupt endocrine systems, promote the development of antibiotic-resistant bacteria, and bioaccumulate in the food chain, ultimately leading to unacceptable risks to public health. The inability of current conventional treatment methods to effectively remove APIs from water has raised serious concerns about the safety and reliability of water supplies. This issue requires immediate attention and the development of more effective treatment technologies to safeguard the quality of water resources and protect both aquatic ecosystems and human health. Other treatment methods, such as nanotechnology, microalgal treatment, and reverse osmosis, are promising in addressing the issue of API contamination in water resources. These innovative approaches have demonstrated higher removal efficiencies for a wide range of APIs compared to conventional methods, such as activated sludge and chlorination, which have been found to be inadequate in the removal of these emerging contaminants. The potential of these alternative treatment technologies to serve as effective tertiary treatment. To address this critical challenge, governments and policymakers should prioritize investment in research and development to establish effective and scalable solutions for eliminating APIs from various water sources. This should include comprehensive studies to assess the performance, cost-effectiveness, and environmental sustainability of emerging treatment technologies. The emerging contaminants should be included in robust water quality monitoring programs (Aus der Beek et al. in Environ Toxicol Chem 2016;35(4):823-835), with strict regulatory limits enforced to protect public health and the environment. By doing so, the scientific community and regulatory authorities can work together to develop a multi-barrier approach to safeguarding the water resources and ensuring access to safe, clean water for all. This review explores the potential of alternative treatment technologies to serve as viable solutions in the fight against API contamination. Innovative approaches, including nanotechnology, microalgal treatment, and reverse osmosis, have demonstrated remarkable success in ad","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"56 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structure based exploration of mitochondrial alpha carbonic anhydrase inhibitors as potential leads for anti-obesity drug development 基于结构探索线粒体α碳酸酐酶抑制剂作为抗肥胖药物开发的潜在线索
IF 3.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-14 DOI: 10.1007/s40199-024-00535-w
Ipsa Padhy, Tripti Sharma, Biswajit Banerjee, Sujata Mohapatra, Chita R. Sahoo, Rabindra Nath Padhy

Background

Obesity has emerged as a major health challenge globally in the last two decades. Dysregulated fatty acid metabolism and de novo lipogenesis are prime causes for obesity development which ultimately trigger other co-morbid pathological conditions thereby risking life longevity. Fatty acid metabolism and de novo lipogenesis involve several biochemical steps both in cytosol and mitochondria. Reportedly, the high catalytically active mitochondrial carbonic anhydrases (CAVA/CAVB) regulate the intercellular depot of bicarbonate ions and catalyze the rapid carboxylation of pyruvate and acetyl-co-A to acetyl-co-A and malonate respectively, which are the precursors of fatty acid synthesis and lipogenesis. Several in vitro and in vivo investigations indicate inhibition of mitochondrial carbonic anhydrase isoforms interfere in the functioning of pyruvate, fatty acid and succinate pathways. Targeting of mitochondrial carbonic anhydrase isoforms (CAVA/CAVB) could thereby modulate gluconeogenetic as well as lipogenetic pathways and pave way for designing of novel leads in the development pipeline of anti-obesity medications.

Methods

The present review unveils a diverse chemical space including synthetic sulphonamides, sulphamates, sulfamides and many natural bioactive molecules which selectively inhibit the mitochondrial isoform CAVA/CAVB with an emphasis on major state-of-art drug design strategies.

Results

More than 60% similarity in the structural framework of the carbonic anhydrase isoforms has converged the drug design methods towards the development of isoform selective chemotypes. While the benzene sulphonamide derivatives selectively inhibit CAVA/CAVB in low nanomolar ranges depending on the substitutions on the phenyl ring, the sulpamates and sulpamides potently inhibit CAVB. The virtual screening and drug repurposing methods have also explored many non-sulphonamide chemical scaffolds which can potently inhibit CAVA.

Conclusion

The review could pave way for the development of novel and effective anti-obesity drugs which can modulate the energy metabolism.

Graphical abstract

背景过去二十年来,肥胖已成为全球面临的一项重大健康挑战。脂肪酸代谢失调和新脂肪生成是导致肥胖的主要原因,最终会引发其他并发症,从而危及寿命。脂肪酸代谢和新脂肪生成涉及细胞质和线粒体中的多个生化步骤。据报道,高催化活性线粒体碳酸酐酶(CAVA/CAVB)可调节细胞间碳酸氢根离子库,并催化丙酮酸和乙酰-Co-A 快速羧化,分别转化为乙酰-Co-A 和丙二酸,后者是脂肪酸合成和脂肪生成的前体。一些体外和体内研究表明,抑制线粒体碳酸酐酶同工酶会干扰丙酮酸、脂肪酸和琥珀酸途径的功能。因此,以线粒体碳酸酐酶同工酶(CAVA/CAVB)为靶点可以调节糖元生成和脂肪生成途径,并为设计抗肥胖药物研发中的新线索铺平道路。方法本综述揭示了一个多样化的化学领域,包括合成磺酰胺类、氨基磺酸盐类、氨基磺酸盐类和许多天然生物活性分子,它们可选择性地抑制线粒体同工酶 CAVA/CAVB,重点介绍了最先进的主要药物设计策略。结果碳酸酐酶同工酶结构框架的相似性超过 60%,这使得药物设计方法趋向于开发同工酶选择性化学类型。苯磺酰胺衍生物可根据苯环上的取代物在低纳摩尔范围内选择性抑制 CAVA/CAVB,而磺胺酸盐和磺胺类化合物则可有效抑制 CAVB。虚拟筛选和药物再利用方法也探索出了许多能有效抑制 CAVA 的非磺酰胺化学支架。
{"title":"Structure based exploration of mitochondrial alpha carbonic anhydrase inhibitors as potential leads for anti-obesity drug development","authors":"Ipsa Padhy, Tripti Sharma, Biswajit Banerjee, Sujata Mohapatra, Chita R. Sahoo, Rabindra Nath Padhy","doi":"10.1007/s40199-024-00535-w","DOIUrl":"https://doi.org/10.1007/s40199-024-00535-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Obesity has emerged as a major health challenge globally in the last two decades. Dysregulated fatty acid metabolism and <i>de novo</i> lipogenesis are prime causes for obesity development which ultimately trigger other co-morbid pathological conditions thereby risking life longevity. Fatty acid metabolism and <i>de novo</i> lipogenesis involve several biochemical steps both in cytosol and mitochondria. Reportedly, the high catalytically active mitochondrial carbonic anhydrases (CAVA/CAVB) regulate the intercellular depot of bicarbonate ions and catalyze the rapid carboxylation of pyruvate and acetyl-co-A to acetyl-co-A and malonate respectively, which are the precursors of fatty acid synthesis and lipogenesis. Several in vitro and in vivo investigations indicate inhibition of mitochondrial carbonic anhydrase isoforms interfere in the functioning of pyruvate, fatty acid and succinate pathways. Targeting of mitochondrial carbonic anhydrase isoforms (CAVA/CAVB) could thereby modulate gluconeogenetic as well as lipogenetic pathways and pave way for designing of novel leads in the development pipeline of anti-obesity medications.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The present review unveils a diverse chemical space including synthetic sulphonamides, sulphamates, sulfamides and many natural bioactive molecules which selectively inhibit the mitochondrial isoform CAVA/CAVB with an emphasis on major state-of-art drug design strategies.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>More than 60% similarity in the structural framework of the carbonic anhydrase isoforms has converged the drug design methods towards the development of isoform selective chemotypes. While the benzene sulphonamide derivatives selectively inhibit CAVA/CAVB in low nanomolar ranges depending on the substitutions on the phenyl ring, the sulpamates and sulpamides potently inhibit CAVB. The virtual screening and drug repurposing methods have also explored many non-sulphonamide chemical scaffolds which can potently inhibit CAVA.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The review could pave way for the development of novel and effective anti-obesity drugs which can modulate the energy metabolism.</p><h3 data-test=\"abstract-sub-heading\">Graphical abstract</h3>\u0000","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"29 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Smoking cessation pharmacotherapy; varenicline or bupropion? 戒烟药物疗法;伐尼克兰还是安非他明?
IF 3.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-12 DOI: 10.1007/s40199-024-00539-6
Fatemeh Rahimi, Ali Massoudifar, Roya Rahimi

Objectives

Tobacco smoking is a worldwide health problem and one of the leading causes of premature deaths in last years. As there are lots of researches focusing on cessation strategies with attention to pharmacotherapy and behavioral counseling, the aim of this study was to compare two of the first-line FDA-approved pharmacotherapies for smoking cessation; varenicline and bupropion.

Evidence acqusition

This writing is an overview of researches published in Pubmed database from 2012 to 2022 with “Varenicline” and “Bupropion” as key words. Among the researches that were found, 24 articles were selected which mainly focused on comparison of these two medicines.

Results

Varenicline and bupropion are known as non-nicotinic pharmacotherapy and have been used in addition to nicotine replacement therapy for smoking cessation. Varenicline is partial agonist for α4β2 nicotinic acetyl choline receptors while bupropion, classified as an atypical antidepressant, is actually a norepinephrine and dopamine reuptake inhibitor. Although these treatments can result in some adverse effects including nausea, insomnia, anxiety, irritability, fatigue and abnormal dreams, their efficacy in reduction of craving and also maintenance of abstinence is well been studied and approved by FDA. Moreover, adverse effects are usually mild to moderate clinical symptoms which can be tolerated and also easily managed and prevented in cases.

Conclusion

The efficacy and tolerability of varenicline and bupropion as treatments for smoking cessation is well understood. However, studies have shown that varenicline seems to be more effective in maintaining of abstinence and also reducing craving than bupropion and NRT.

目的吸烟是一个世界性的健康问题,也是近年来导致过早死亡的主要原因之一。由于有很多研究关注药物疗法和行为咨询的戒烟策略,本研究旨在比较两种经 FDA 批准的一线戒烟药物疗法:伐尼克兰和安非他酮。结果伐尼克兰和安非他酮被称为非烟碱类药物疗法,已被用于尼古丁替代疗法之外的戒烟治疗。伐尼克兰是α4β2烟碱乙酰胆碱受体的部分激动剂,而被归类为非典型抗抑郁药的安非他酮实际上是去甲肾上腺素和多巴胺再摄取抑制剂。虽然这些治疗方法会导致一些不良反应,包括恶心、失眠、焦虑、易怒、疲劳和梦境异常,但它们在减少渴求和维持戒断方面的疗效已经过充分研究,并获得了美国食品和药物管理局的批准。此外,不良反应通常是轻度至中度的临床症状,可以耐受,也很容易控制和预防。结论人们已经充分了解伐尼克兰和安非他酮作为戒烟治疗药物的疗效和耐受性。然而,研究表明,与安非他酮和 NRT 相比,伐尼克兰在维持戒烟和减少烟瘾方面似乎更有效。
{"title":"Smoking cessation pharmacotherapy; varenicline or bupropion?","authors":"Fatemeh Rahimi, Ali Massoudifar, Roya Rahimi","doi":"10.1007/s40199-024-00539-6","DOIUrl":"https://doi.org/10.1007/s40199-024-00539-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>Tobacco smoking is a worldwide health problem and one of the leading causes of premature deaths in last years. As there are lots of researches focusing on cessation strategies with attention to pharmacotherapy and behavioral counseling, the aim of this study was to compare two of the first-line FDA-approved pharmacotherapies for smoking cessation; varenicline and bupropion.</p><h3 data-test=\"abstract-sub-heading\">Evidence acqusition</h3><p>This writing is an overview of researches published in Pubmed database from 2012 to 2022 with “Varenicline” and “Bupropion” as key words. Among the researches that were found, 24 articles were selected which mainly focused on comparison of these two medicines.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Varenicline and bupropion are known as non-nicotinic pharmacotherapy and have been used in addition to nicotine replacement therapy for smoking cessation. Varenicline is partial agonist for α4β2 nicotinic acetyl choline receptors while bupropion, classified as an atypical antidepressant, is actually a norepinephrine and dopamine reuptake inhibitor. Although these treatments can result in some adverse effects including nausea, insomnia, anxiety, irritability, fatigue and abnormal dreams, their efficacy in reduction of craving and also maintenance of abstinence is well been studied and approved by FDA. Moreover, adverse effects are usually mild to moderate clinical symptoms which can be tolerated and also easily managed and prevented in cases.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The efficacy and tolerability of varenicline and bupropion as treatments for smoking cessation is well understood. However, studies have shown that varenicline seems to be more effective in maintaining of abstinence and also reducing craving than bupropion and NRT.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"305 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142217786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Freeze-drying of bupivacaine lipospheres: preparation, characterization, and evaluation of anti-microbial properties. 冷冻干燥布比卡因脂球:制备、表征和抗微生物特性评估。
IF 3.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-01 Epub Date: 2024-02-29 DOI: 10.1007/s40199-024-00506-1
Sepehr Labanian, Homa Faghihi, Hamed Montazeri, Aliakbar Jafarian

Purpose: To prepare freeze-dried bupivacaine lipospheres intended for topical application in burn injuries. The aim was improving the storage stability and developing a prolonged release pattern to tackle the adverse reactions resulting from the frequent administration of bupivacaine.

Methods: The lipospheres were prepared by hot-melt dispersion method employing bupivacaine base at 1.5 and 3%w/w, tristearin 6% w/w as the core while dipalmitoyl phosphatidylcholine (DPPC) and soy phosphatidylcholine (SPC) as the coat at 0.75, 1.5 and 3% w/w. The lotion was then freeze-dried and cryoprotected by sucrose 3% w/w. Evaluation was carried out through loading and release analysis, storage study, particle characterization including morphology, zeta potential and particle size as well as anti-microbial assessment.

Results: The highest loading, (87.6 ± 0.1%), was achieved using bupivacaine 3% and SPC 0.75%. After 6 months of storage at 4 ͦC, the loading in the lotion and the freeze-dried samples were 17.4 ± 0.2 and 87.2 ± 0.3%, respectively. In vitro dissolution test demonstrated 94.5% and 95% of bupivacaine release from lotion and freeze-dried samples, after 24 h. The respective zeta potential of -1.30 and 26 mV was recorded for lotion and solid-state bupivacaine. Micromeritic evaluation of freeze-dried powder exhibited particle size of 35.23 ± 2.02 μm and highly-wrinkled-irregular morphology without detectable needle structures related to drug free crystals. The powder had rapid reconstitution property and antibacterial activity.

Conclusion: Freeze- drying holds a promising potential to improve the storage stability of bupivacaine lipospheres with well- preserved release pattern and particle properties for further topical application.

目的:制备用于烧伤局部用药的冻干布比卡因脂球。目的是提高其储存稳定性,并开发一种长效释放模式,以解决因频繁使用布比卡因而产生的不良反应:采用热熔分散法制备脂球,以 1.5% 和 3% w/w 的布比卡因为基质,以 6% w/w 的三硬脂苷为核心,以 0.75、1.5 和 3% w/w 的二棕榈酰基磷脂酰胆碱 (DPPC) 和大豆磷脂酰胆碱 (SPC) 为外层。然后对乳液进行冷冻干燥,并用 3% w/w 的蔗糖进行低温保护。通过负载和释放分析、储存研究、颗粒表征(包括形态、ZETA电位和粒度)以及抗微生物评估进行了评估:结果:布比卡因 3% 和 SPC 0.75% 的负载量最高(87.6 ± 0.1%)。在 4 ͦC 下保存 6 个月后,乳液和冻干样品的负载量分别为 17.4 ± 0.2 和 87.2 ± 0.3%。体外溶解试验表明,24 小时后,布比卡因分别从乳液和冻干样品中释放了 94.5% 和 95%。对冻干粉末进行的微观评价显示,其粒径为 35.23 ± 2.02 μm,形态为高度皱缩的不规则状,未发现与药物游离晶体有关的针状结构。该粉末具有快速复溶特性和抗菌活性:冷冻干燥法有望提高布比卡因脂球的贮存稳定性,并能很好地保留释放模式和颗粒特性,以便进一步局部应用。
{"title":"Freeze-drying of bupivacaine lipospheres: preparation, characterization, and evaluation of anti-microbial properties.","authors":"Sepehr Labanian, Homa Faghihi, Hamed Montazeri, Aliakbar Jafarian","doi":"10.1007/s40199-024-00506-1","DOIUrl":"10.1007/s40199-024-00506-1","url":null,"abstract":"<p><strong>Purpose: </strong>To prepare freeze-dried bupivacaine lipospheres intended for topical application in burn injuries. The aim was improving the storage stability and developing a prolonged release pattern to tackle the adverse reactions resulting from the frequent administration of bupivacaine.</p><p><strong>Methods: </strong>The lipospheres were prepared by hot-melt dispersion method employing bupivacaine base at 1.5 and 3%w/w, tristearin 6% w/w as the core while dipalmitoyl phosphatidylcholine (DPPC) and soy phosphatidylcholine (SPC) as the coat at 0.75, 1.5 and 3% w/w. The lotion was then freeze-dried and cryoprotected by sucrose 3% w/w. Evaluation was carried out through loading and release analysis, storage study, particle characterization including morphology, zeta potential and particle size as well as anti-microbial assessment.</p><p><strong>Results: </strong>The highest loading, (87.6 ± 0.1%), was achieved using bupivacaine 3% and SPC 0.75%. After 6 months of storage at 4 ͦC, the loading in the lotion and the freeze-dried samples were 17.4 ± 0.2 and 87.2 ± 0.3%, respectively. In vitro dissolution test demonstrated 94.5% and 95% of bupivacaine release from lotion and freeze-dried samples, after 24 h. The respective zeta potential of -1.30 and 26 mV was recorded for lotion and solid-state bupivacaine. Micromeritic evaluation of freeze-dried powder exhibited particle size of 35.23 ± 2.02 μm and highly-wrinkled-irregular morphology without detectable needle structures related to drug free crystals. The powder had rapid reconstitution property and antibacterial activity.</p><p><strong>Conclusion: </strong>Freeze- drying holds a promising potential to improve the storage stability of bupivacaine lipospheres with well- preserved release pattern and particle properties for further topical application.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"207-214"},"PeriodicalIF":3.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11087389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139989515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
DARU Journal of Pharmaceutical Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1